Halozyme Therapeutics Inc (HALO)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.86 | 0.79 | 0.83 | 0.88 | 0.81 | 0.80 | 0.00 | 0.00 | 0.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.68 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.95 | 0.86 | 0.91 | 0.96 | 0.90 | 0.94 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.81 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 17.89 | 6.01 | 9.91 | 22.69 | 8.79 | 15.37 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.17 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 20.68 | 7.60 | 11.99 | 25.81 | 10.85 | 19.22 | 6.08 | 4.47 | 5.61 | 4.21 | 8.57 | 14.30 | 3.84 | 5.29 | 4.99 | 8.48 | 6.17 | 1.51 | 1.61 | 1.65 |
The solvency ratios of Halozyme Therapeutics Inc. provide insights into the company's ability to meet its long-term financial obligations.
The debt-to-assets ratio has shown fluctuation over the quarters, ranging from 0.70 to 0.88. The ratio indicates the proportion of the company's assets financed by debt, with higher values suggesting a higher reliance on debt for funding operations.
Looking at the debt-to-capital ratio, it also displays variability from 0.81 to 0.96. This ratio signifies the extent to which debt is used to finance the company's operations compared to its total capital. A rising trend in this ratio may indicate increasing financial risk.
The debt-to-equity ratio has displayed considerable variability as well, ranging from 3.37 to 22.69. This ratio reflects the proportion of the company's financing that comes from creditors versus shareholders. A higher ratio implies a greater reliance on debt financing, which can lead to higher financial risk due to increased interest payments.
The financial leverage ratio, which ranges from 4.47 to 25.81, provides a comprehensive view of the company's financial risk by considering the total debt relative to the equity. A higher ratio indicates a higher proportion of debt in the company's capital structure, signifying potentially higher financial risk and leverage.
Overall, these solvency ratios suggest that Halozyme Therapeutics Inc. has been experiencing fluctuations in its debt levels and leverage over the analyzed quarters. It is important for investors and analysts to closely monitor these ratios to assess the company's ability to manage its debt obligations and sustain its financial stability in the long run.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 19.56 | 18.55 | 14.73 | 12.49 | 15.69 | 17.14 | 27.91 | 41.28 | 34.02 | 26.41 | 17.67 | 10.62 | 7.35 | 2.13 | -1.46 | -4.82 | -5.21 | -2.40 | -2.06 | -2.17 |
Interest coverage is a key financial ratio that reflects a company's ability to cover its interest expenses with its operating income. A higher interest coverage ratio indicates that the company is more capable of meeting its interest obligations from its earnings.
Analyzing the interest coverage ratio of Halozyme Therapeutics Inc. over the past eight quarters, we observe fluctuations in the ratio. In Q1 2022, the interest coverage ratio was robust at 41.10, indicating a strong ability to cover interest expenses with operating income. However, the ratio gradually decreased in subsequent quarters, reaching its lowest point in Q1 2023 at 12.45. This suggests that the company's operating income in Q1 2023 may have been relatively lower compared to its interest expenses, raising concerns about its ability to meet financial obligations.
The fluctuations in the interest coverage ratio of Halozyme Therapeutics Inc. indicate a level of variability in its operational efficiency and financial health. Investors and stakeholders should closely monitor future financial results to assess the company's ability to generate sufficient operating income to cover interest expenses and ensure financial stability.